Stock FOLD AMICUS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Amicus Therapeutics, Inc.

Equities

FOLD

US03152W1099

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-19 pm EDT 		5-day change 1st Jan Change
10.61 USD +2.71% Intraday chart for Amicus Therapeutics, Inc. -0.66% -25.23%
Mar. 18 JPMorgan Adjusts Price Target on Amicus Therapeutics to $19 From $21, Maintains Overweight Rating MT
Mar. 05 Amicus Therapeutics Insider Sold Shares Worth $389,543, According to a Recent SEC Filing MT

Business Summary

Amicus Therapeutics, Inc. is a biotechnology company, which is focused on discovering, developing, and delivering novel medicines for rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a novel treatment designed to improve uptake of active enzyme into key disease relevant tissues for adults living with late-onset Pompe disease. As an orally administered monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice (GLP) cell-based amenability assay. Pombiliti + Opfolda consists of a uniquely engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with miglustat that functions as an enzyme stabilizer.

Number of employees: 517

Sales per Business

USD in Million2022Weight2023Weight Delta
Advanced Therapies
100.0 %
329 100.0 % 399 100.0 % +21.30%

Sales per region

USD in Million2022Weight2023Weight Delta
Non-United States
63.2 %
213 64.8 % 252 63.2 % +18.35%
United States
36.8 %
116 35.2 % 147 36.8 % +26.73%

Managers

Managers TitleAgeSince
Bradley Campbell CEO
 Chief Executive Officer 48 06-03-31
Simon Harford DFI
 Director of Finance/CFO 64 23-08-20
Pat O’Sullivan COO
 Chief Operating Officer - 22-06-30
Mitchell Goldman CTO
 Chief Tech/Sci/R&D Officer - 19-12-31
Jill Weimer CTO
 Chief Tech/Sci/R&D Officer - 19-06-12
Patrik Florencio CMP
 Compliance Officer - 15-07-31
Andrew Faughnan IRC
 Investor Relations Contact - -
Stephen Arnold PRN
 Corporate Officer/Principal - Oct. 31
David Clark HRO
 Human Resources Officer 49 18-09-30
Samantha Prout AUD
 Comptroller/Controller/Auditor 46 18-02-28

Members of the board

Members of the board TitleAgeSince
Bradley Campbell CEO
 Chief Executive Officer 48 06-03-31
Lynn Bleil BRD
 Director/Board Member 60 18-09-10
Burke W. Whitman BRD
 Director/Board Member 68 19-06-26
Margaret McGlynn BRD
 Director/Board Member 64 09-09-30
Michael Kelly BRD
 Director/Board Member 67 20-11-30
Glenn Sblendorio BRD
 Director/Board Member 68 06-05-31
Craig Wheeler BRD
 Director/Board Member 63 16-06-09
Mike Raab Raab CHM
 Chairman 59 03-12-31
Eiry Roberts BRD
 Director/Board Member 60 21-06-09

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 295,382,614 265,100,314 ( 89.75 %) 0 89.75 %

Shareholders

NameEquities%Valuation
Vanguard Fiduciary Trust Co.
9.646 %
28,492,486 9.646 % 336 M $
Perceptive Advisors LLC
9.499 %
28,057,456 9.499 % 331 M $
Avoro Capital Advisor LLC
9.276 %
27,400,000 9.276 % 323 M $
BlackRock Advisors LLC
7.388 %
21,821,821 7.388 % 257 M $
JPMorgan Investment Management, Inc.
6.043 %
17,848,531 6.043 % 210 M $
Wellington Management Co. LLP
5.142 %
15,190,024 5.142 % 179 M $
Redmile Group LLC
5.020 %
14,828,321 5.020 % 175 M $
Morgan Stanley Investment Management, Inc.
4.512 %
13,327,897 4.512 % 157 M $
STATE STREET CORPORATION
4.456 %
13,163,085 4.456 % 155 M $
William Blair Investment Management LLC
3.943 %
11,647,026 3.943 % 137 M $

Company contact information

Amicus Therapeutics, Inc.

47 Hulfish Street

08542, Princeton

+609 662 2000

http://www.amicusrx.com
address Amicus Therapeutics, Inc.(FOLD)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per region

Ratings for Amicus Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
10.61 USD
Average target price
18.78 USD
Spread / Average Target
+76.98%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
AMICUS THERAPEUTICS, INC. Stock Amicus Therapeutics, Inc.
-25.23% 3.13B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.42% 41.52B
LONZA GROUP AG Stock Lonza Group AG
+42.15% 39.9B
MODERNA, INC. Stock Moderna, Inc.
+1.97% 38.83B
CELLTRION, INC. Stock Celltrion, Inc.
-14.19% 26.05B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+1.82% 23.78B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.55% 18.26B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-4.07% 11.65B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+21.36% 11.53B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+8.20% 11.2B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. FOLD Stock
  4. Company Amicus Therapeutics, Inc.